Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress

Kling Biotherapeutics Netherlands United Kingdom United States of America

under identifier NCT05501821.

About ESMO

ESMO's core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate – doctors, cancer patients and the general public – on the best practices and latest advances in oncology. And it is to promote equal access to optimal cancer care for all patients.

View original content:https://www.prnewswire.co.uk/news-releases/kling-biotherapeutics-to-present-discoveries-on-its-primary-b-cell-screening-platform-at-the-esmo-targeted-anticancer-therapies-congress-302067643.html